| Name | Title | Contact Details |
|---|
K-LaB Technologies, Inc. is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Invicro, A Konica Minolta Company, was founded with a mission of improving the role and function of imaging in translational drug discovery and development. To this effort we offer a suite of services and software with applications ranging from tissue to human, from target identification to Phase IV trials across the entire electromagnetic spectrum of imaging techniques. We start all projects with a data-driven mentality and the knowledge that quality data are the key to solving scientific challenges. Our analytics team is constantly innovating to develop the processes by which true and valuable quantitative information is extracted. Our approach has always been one of a scientific partner and collaborator, offering the service of our 200+ researchers on our team from a broad array of disciplines.
Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company`s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara`s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.
Intellikine is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.